| Development of new PTK7-targeting aptamer-fluorescent and-radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept V Calzada, M Moreno, J Newton, J González, M Fernández, JP Gambini, ... Bioorganic & medicinal chemistry 25 (3), 1163-1171, 2017 | 42 | 2017 |
| The minimum aptamer publication standards (MAPS guidelines) for de novo aptamer selection M McKeague, V Calzada, L Cerchia, M DeRosa, JM Heemstra, N Janjic, ... Aptamers 6, 2022 | 28 | 2022 |
| [99mTc (CO) 3]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model X Camacho, MF García, V Calzada, M Fernández, JA Chabalgoity, ... Oncology 84 (4), 200-209, 2013 | 28 | 2013 |
| Sgc8-c Aptamer as a Potential Theranostic Agent for Hemato-Oncological Malignancies VC Estefanía Sicco, Jessica Baez, Manuel Ibarra, Marcelo Fernández, Pablo ... Cancer Biotherapy & Radiopharmaceuticals 35 (4), 2020 | 25 | 2020 |
| Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody MF Garcia, V Calzada, X Camacho, E Goicochea, J Pablo Gambini, ... Current Radiopharmaceuticals 7 (2), 84-90, 2014 | 23 | 2014 |
| Metastatic and non-metastatic melanoma imaging using Sgc8-c aptamer PTK7-recognizer E Sicco, A Mónaco, M Fernandez, M Moreno, V Calzada, H Cerecetto Scientific Reports 11 (1), 19942, 2021 | 18 | 2021 |
| Sequence-dependent structural properties of B-DNA: what have we learned in 40 years? G Da Rosa, L Grille, V Calzada, K Ahmad, JP Arcon, F Battistini, G Bayarri, ... Biophysical Reviews, 1-11, 2021 | 17 | 2021 |
| Derivatizations of Sgc8‐c aptamer to prepare metallic radiopharmaceuticals as imaging diagnostic agents: Syntheses, isolations, and physicochemical characterizations E Sicco, J Báez, J Margenat, F García, M Ibarra, P Cabral, M Moreno, ... Chemical biology & drug design, 2017 | 16 | 2017 |
| 99mTc-labeled Bevacizumab vía HYNIC for Imaging of Melanoma X Camacho, MF García, V Calzada, M Fernandez, O Alonso, JP Gambini, ... Journal of Analytical Oncology 3 (1), 53-64, 2014 | 16 | 2014 |
| Aptamers in diagnostic and molecular imaging applications V Calzada Aptamers in biotechnology, 141-160, 2020 | 14 | 2020 |
| Fab (nimotuzumab)-HYNIC-99mTc: Antibody fragmentation for molecular imaging agents V Calzada, MF García, LM Alonso-Martínez, X Camachoc, E Goicochea, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2016 | 14 | 2016 |
| Synthesis and evaluation of 99mTc chelate-conjugated bevacizumab X Camacho, M Fernanda Garcia, V Calzada, M Fernández, W Porcal, ... Current Radiopharmaceuticals 6 (1), 12-19, 2013 | 14 | 2013 |
| Labeling and biological evaluation of 99mTc-HYNIC-Trastuzumab as a potential radiopharmaceutical for in vivo evaluation of HER2 expression in breast cancer V Calzada, F Garcia, M Fernández, W Porcal, T Quinn, O Alonso, ... World Journal of Nuclear Medicine 12 (1), 27, 2013 | 14 | 2013 |
| T908 polymeric micelles improved the uptake of Sgc8-c aptamer probe in tumor-bearing mice: A co-association study between the probe and preformed nanostructures R Castelli, M Ibarra, R Faccio, I Miraballes, M Fernández, A Moglioni, ... Pharmaceuticals 15 (1), 15, 2021 | 12 | 2021 |
| Preliminary in vivo characterization of a theranostic aptamer: Sgc8-c-DOTA-67Ga. V Calzada, J Báez, E Sicco, J Margenat, M Fernández, M Moreno, ... Aptamers 1, 2017 | 12 | 2017 |
| A potencial theranostic agent for EGF-R expression tumors: 177Lu-DOTA-Nimotuzumab V Calzada, X Zhang, M Fernández, A Díaz-Miqueli, N Iznaga-Escobar, ... Current Radiopharmaceuticals 5 (4), 318-324, 2012 | 12 | 2012 |
| In vitro and in vivo evaluation of [99mTc (CO) 3]-radiolabeled ErbB-2-targeting peptides for breast carcinoma imaging X Zhang, P Cabral, M Bates, J Pablo Gambini, M Fernandez, V Calzada, ... Current Radiopharmaceuticals 3 (4), 308-321, 2010 | 9 | 2010 |
| In vivo evaluation of Sgc8-c aptamer as a molecular imaging probe for colon cancer in a mouse xenograft model AP Arévalo, R Castelli, M Ibarra, M Crispo, V Calzada International Journal of Molecular Sciences 23 (5), 2466, 2022 | 8 | 2022 |
| 177Lu-DOTA-Bevacizumab: Radioimmunotherapy agent for melanoma X Camacho, V Calzada, M Fernandez, O Alonso, R Chammas, E Riva, ... Current radiopharmaceuticals 10 (1), 21-28, 2017 | 8 | 2017 |
| Cursos masivos: ampliando expectativas V Calzada, N Lecot, MF García, M Cabrera, X Camacho, M Tassano, ... Educación Química 25, 254-257, 2014 | 8 | 2014 |
